Rivaroxaban: An Evaluation of its Cardiovascular Benefit–Risk Profile Across Indications Based on Numbers Needed to Treat or Harm, and on Clinically Meaningful Endpoint Comparisons
Crossref DOI link: https://doi.org/10.1007/s40268-015-0105-9
Published Online: 2015-09-28
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ageno, Walter
License valid from 2015-09-28